Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma

(2021) Caterina Gianni et al.   Frontiers in Pharmacology

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature

(2020) Izumi Sato et al.   Medicina-Lithuania

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma

(2020) Hiroaki Kodama et al.   INVESTIGATIONAL NEW DRUGS

Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer

(2019) Yi-Tsz Lin et al.   LUNG CANCER

Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib

(2019) A J Schoenfeld et al.   ANNALS OF ONCOLOGY

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

(2018) Chia‐Yu Chu et al.   ONCOLOGIST

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab

(2017) Nobuaki Mamesaya et al.   INVESTIGATIONAL NEW DRUGS

Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity

(2017) Hironori Yoshida et al.   Journal of Thoracic Oncology